Displaying drugs 251 - 275 of 11638 in total
Atriplex confertifolia pollen
Atriplex confertifolia pollen is the pollen of the Atriplex confertifolia plant. Atriplex confertifolia pollen is mainly used in allergenic testing.
Approved
Cimetidine
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Approved
Investigational
Matched Description: … Cimetidine has a range of pharmacological actions. ... A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. …
Valproic acid
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into...
Approved
Investigational
Matched Description: … nearly a century. ... is the subject of many clinical trials in a variety of cancer types. ... [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... UGT1A3 Substrates with a Narrow Therapeutic Index ... UGT1A6 Substrates with a Narrow Therapeutic Index ... UGT1A9 Substrates with a Narrow Therapeutic Index ... UGT2B7 Substrates with a Narrow Therapeutic Index …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... UGT1A3 Substrates with a Narrow Therapeutic Index ... UGT1A6 Substrates with a Narrow Therapeutic Index ... UGT1A9 Substrates with a Narrow Therapeutic Index ... UGT2B7 Substrates with a Narrow Therapeutic Index …
Fezolinetant
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Iupac: … 5-[(8R)-7-(4-fluorobenzoyl)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-3-methyl-1,2,4-thiadiazole …
Matched Description: … With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek ... [A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms can significantly affect ... quality of life, as women with 7 or more moderate to severe VMS daily have reported a decline in sleep …
Matched Description: … With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek ... [A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms can significantly affect ... quality of life, as women with 7 or more moderate to severe VMS daily have reported a decline in sleep …
Axitinib
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
D-alpha-Tocopherol acetate
Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. In particular, the RRR-alpha-tocopherol (or sometimes called the d-alpha-tocopherol stereoisomer) stereoisomer is considered the natural formation of alpha-tocopherol and generally exhibits the greatest bioavailability out of all of the...
Approved
Nutraceutical
Vet approved
Matched Description: … used as a food additive when needed [A32451]. ... subsequently most commonly indicated for dietary supplementation in individuals who may demonstrate a ... is naturally found in various foods, added to others, or used in commercially available products as a …
Matched Mixtures name: … Vitamin A C E W.niacinam.beta Car.and Min. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Mixtures name: … Vitamin A C E W.niacinam.beta Car.and Min. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Cobimetinib
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Categories: … UGT2B7 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Troglitazone
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Deferoxamine
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... [L8336,L8339]
On a weight basis, methimazole is 10 times more potent than the other major antithyroid ... hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a …
Idelalisib
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities ... Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic ... For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …
Abatacept
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes ... [L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight ... of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. …
Sotagliflozin
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal ... Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a …
Procarbazine
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Approved
Investigational
Procainamide
A derivative of procaine with less CNS action.
Approved
Matched Description: … A derivative of procaine with less CNS action. …
Matched Categories: … OCT2 Substrates with a Narrow Therapeutic Index ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …
Matched Categories: … OCT2 Substrates with a Narrow Therapeutic Index ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …
Hydrocortisone
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Approved
Vet approved
Matched Iupac: … 1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. …
Matched Mixtures name: … Cho-A Care Lot 1% …
Matched Products: … SKIN A COOL Hydrocortisone Anti-Itch …
Matched Description: … Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. …
Matched Mixtures name: … Cho-A Care Lot 1% …
Matched Products: … SKIN A COOL Hydrocortisone Anti-Itch …
Adefovir dipivoxil
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
Approved
Investigational
Matched International brands: … A Di Xian ... A Gan Ding …
Starch, corn
Corn starch refers to the starch extracted from the corn grain that is commonly used as a food ingredient and chemical additive. Starch is any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin. Starch...
Approved
Nutraceutical
Matched Description: … Starch is any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain ... found in topical drugs as a skin protectant. ... Corn starch refers to the starch extracted from the corn grain that is commonly used as a food ingredient …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Acetic acid
Acetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or...
Approved
Matched Description: … It is used locally, occasionally internally, as a counterirritant and also as a reagent. ... Acetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. …
Matched Mixtures name: … POLYLAB T-EUSOL (SOLUTION A & B) ... POLYLAB T-EUSOL( SOLUTION A & B) ... SC Pharma Eusol Solution Max A & B …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Mixtures name: … POLYLAB T-EUSOL (SOLUTION A & B) ... POLYLAB T-EUSOL( SOLUTION A & B) ... SC Pharma Eusol Solution Max A & B …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Glycerol phenylbutyrate
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Description: … Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol ... Glycerol phenylbutyrate is a nitrogen-binding agent. …
Hydrochlorothiazide
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459]
Hydrochlorothiazide was granted FDA...
Approved
Vet approved
Matched Mixtures name: … CO-IRVELL ... CO-DIOVAN ... CO-DIOVAN …
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a …
Beremagene geperpavec
Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Description: … Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector ... [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component …
Displaying drugs 251 - 275 of 11638 in total